01662nas a2200205   4500000000100000008004100001260001000042653002300052653002600075653002100101653002900122100001800151700001800169700001400187700001700201700002500218245007800243520111000321022002501431       2024                            d  bWiley10aLeprosy management10aPeripheral neuropathy10apolychemotherapy10aResearch and development1 aMoreira LMCDC1 aOliveira ACDJ1 aChaves LL1 aSoares MFDLR1 aSoares‐Sobrinho JL00aFrom Challenges to Solution: The Evolving Landscape of Leprosy Management3 a<p>Leprosy, caused by Mycobacterium leprae, despite being a curable disease when treated can induce peripheral neuropathy. However, the medicines used in polychemotherapy promote several side effects. Thus, research for the development of new administration systems is an alternative, but there is a lack of preclinical and clinical studies of the systems, where 90.90% have a level of technological maturity 3 and 9.09% level 4. The main issues are associated with deficiencies in vitro and in vivo cultivation methodologies, lack of financing, as well as the disinterest of the pharmaceutical industry in investing in neglected tropical diseases. In addition, with the emergence of resistant bacteria, there is urgency in the search for vaccines and, therefore, in the expansion of immunomodulation studies to define the molecular targets of the vaccine and future medications. In addition, future treatments for various diseases, including leprosy, will be directly influenced by the evolution of additive manufacturing and 3D printing, seeking personalized, flexible, and reproducible treatment.</p>
  a2366-3987, 2366-3987